Lower dose prostate cancer treatments retain efficacy while improving tolerability. (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

Lower dose prostate cancer treatments retain efficacy while improving tolerability.

Caption

Figure 2. (A–D) Patient with meningeal, adrenal, pulmonary, lymph nodal, and osseous metastases. (A) Baseline staging per 18F-PSMA-1007 PET/CT is demonstrated as maximum-intensity projection. (B and C) Two cycles of AcPSMA and LuPSMA cocktail therapy were documented per planar scan of 208-keV γ-line of 177Lu. (D) PET/CT restaging presents partial remission. (E–H) Patient with adrenal, osseous, lymph nodal, and hepatic metastases. (E) Baseline imaging was done as planar 99mTc-PSMA scintigraphy. (F and G) AcPSMA monotherapy was documented per planar emission scans using 26% 440-keV and 12% 218-keV γ-coemissions of 213Bi and 221Fr. (H) Restaging per planar 99mTc-PSMA scintigraphy demonstrates near-total remission.

Credit

Image created by H Rathke and C Kratochwil, et al., Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.

Usage Restrictions

Please give appropriate credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.